Metformin protects against systolic overload-induced heart failure independent of AMP-activated protein kinase α2

Hypertension

Volumn 63, Issue 4, 2014, Pages 723-728

  Xu, Xin ^a   Lu, Zhongbing ^a,c   Fassett, John ^a   Zhang, Ping ^a   Hu, Xinli ^a   Liu, Xiaoyu ^a   Kwak, Dongmin ^a   Li, Jingxin ^a   Zhu, Guangshuo ^a   Tao, Yi ^a   Hou, Mingxiao ^d   Wang, Huan ^a   Guo, Haipeng ^d   Viollet, Benoit ^e   McFalls, Edward O ^b   Bache, Robert J ^a   Chen, Yingjie ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^d GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^e INSTITUT COCHIN   (France)

Author keywords

heart failure; hypertrophy; metformin; ortic banding

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ALPHA1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ALPHA2; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME PHOSPHORYLATION; GENE INACTIVATION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HEART VENTRICLE OVERLOAD; KNOCKOUT MOUSE; LUNG WEIGHT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WILD TYPE;

AORTIC BANDING; HEART FAILURE; HYPERTROPHY; METFORMIN;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; AORTA; DISEASE MODELS, ANIMAL; HEART FAILURE, SYSTOLIC; HYPERTROPHY, LEFT VENTRICULAR; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SIGNAL TRANSDUCTION; STROKE VOLUME; VASOCONSTRICTION;

EID: 84897072824     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.02619     Document Type: Article

References (27)

1. Zhang P, Hu X, Xu X, Fassett J, Zhu G, Viollet B, Xu W, Wiczer B, Bernlohr DA, Bache RJ, Chen Y. AMP activated protein kinase-alpha2 defciency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension. 2008;52:918-924.
2. Tian R, Musi N, D'Agostino J, Hirshman MF, Goodyear LJ. Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation. 2001;104:1664-1669.
3. Sasaki H, Asanuma H, Fujita M, et al. Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation. 2009;119:2568-2577.
4. Hu X, Xu X, Lu Z, Zhang P, Fassett J, Zhang Y, Xin Y, Hall JL, Viollet B, Bache RJ, Huang Y, Chen Y. AMP activated protein kinase-α2 regulates expression of estrogen-related receptor-α, a metabolic transcription factor related to heart failure development. Hypertension. 2011;58:696-703.
5. Fassett JT, Hu X, Xu X, Lu Z, Zhang P, Chen Y, Bache RJ. AMPK attenuates microtubule proliferation in cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2013;304:H749-H758.
6. Masoudi FA, Wang Y, Inzucchi SE, Setaro JF, Havranek EP, Foody JM, Krumholz HM. Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA. 2003;290:81-85.
7. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005;111:583-590.
8. Xiao H, Ma X, Feng W, Fu Y, Lu Z, Xu M, Shen Q, Zhu Y, Zhang Y. Metformin attenuates cardiac fbrosis by inhibiting the TGFbeta1-Smad3 signalling pathway. Cardiovasc Res. 2010;87:504-513.
9. Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, Nunez D, Ramachandran A, Anaya-Cisneros M, Tian R, Lefer DJ. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res. 2009;104:403-411.
10. Jørgensen SB, Viollet B, Andreelli F, Frøsig C, Birk JB, Schjerling P, Vaulont S, Richter EA, Wojtaszewski JF. Knockout of the alpha2 but not alpha1 5'-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranosidebut not contraction-induced glucose uptake in skeletal muscle. J Biol Chem. 2004;279:1070-1079.
11. Viollet B, Andreelli F, Jørgensen SB, et al. The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. J Clin Invest. 2003;111:91-98.
12. Hu P, Zhang D, Swenson L, Chakrabarti G, Abel ED, Litwin SE. Minimally invasive aortic banding in mice: effects of altered cardiomyo-cyte insulin signaling during pressure overload. Am J Physiol Heart Circ Physiol. 2003;285:H1261-H1269.
13. Lu Z, Fassett J, Xu X, Hu X, Zhu G, French J, Zhang P, Schnermann J, Bache RJ, Chen Y. Adenosine A3 receptor defciency exerts unanticipated protective effects on the pressure-overloaded left ventricle. Circulation. 2008;118:1713-1721.
14. Song P, Wang S, He C, Wang S, Liang B, Viollet B, Zou MH. AMPKα2 deletion exacerbates neointima formation by upregulating Skp2 in vascular smooth muscle cells. Circ Res. 2011;109:1230-1239.
15. Wang S, Zhang C, Zhang M, Liang B, Zhu H, Lee J, Viollet B, Xia L, Zhang Y, Zou MH. Activation of AMP-activated protein kinase α2 by nicotine instigates formation of abdominal aortic aneurysms in mice in vivo. Nat Med. 2012;18:902-910.
16. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34): Lancet. 1998; 352:854-865.
17. Eurich DT, McAlister FA, Blackburn DF, Majumdar SR, Tsuyuki RT, Varney J, Johnson JA. Benefts and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ. 2007;335:497.
18. Fu YN, Xiao H, Ma XW, Jiang SY, Xu M, Zhang YY. Metformin attenuates pressure overload-induced cardiac hypertrophy via AMPK activation. Acta Pharmacol Sin. 2011;32:879-887.
19. Foretz M, Hébrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F, Viollet B. Metformin inhibits hepatic gluco-neogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010;120:2355-2369.
20. Stephenne X, Foretz M, Taleux N, van der Zon GC, Sokal E, Hue L, Viollet B, Guigas B. Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia. 2011;54:3101-3110.
21. Paiva M, Riksen NP, Davidson SM, Hausenloy DJ, Monteiro P, Gonçalves L, Providência L, Rongen GA, Smits P, Mocanu MM, Yellon DM. Metformin prevents myocardial reperfusion injury by activating the ade-nosine receptor. J Cardiovasc Pharmacol. 2009;53:373-378.
22. Xu X, Fassett J, Hu X, Zhu G, Lu Z, Li Y, Schnermann J, Bache RJ, Chen Y. Ecto-5'-nucleotidase defciency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction. Hypertension. 2008;51:1557-1564.
23. Fassett JT, Hu X, Xu X, Lu Z, Zhang P, Chen Y, Bache RJ. Adenosine kinase regulation of cardiomyocyte hypertrophy. Am J Physiol Heart Circ Physiol. 2011;300:H1722-H1732.
24. Kalender A, Selvaraj A, Kim SY, Gulati P, Brûlé S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, Marette A, Kozma SC, Thomas G. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2010;11:390-401.
25. Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P, Tanti JF, Giorgetti-Peraldi S, Bost F. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 2011;71:4366-4372.
26. Lin CC, Yeh HH, Huang WL, Yan JJ, Lai WW, Su WP, Chen HH, Su WC. Metformin Enhances Cisplatin Cytotoxicity by Suppressing Stat3 Activity Independently of the LKB1-AMPK Pathway. Am J Respir Cell Mol Biol. 2013;49:241-250.
27. Kunisada K, Negoro S, Tone E, Funamoto M, Osugi T, Yamada S, Okabe M, Kishimoto T, Yamauchi-Takihara K. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. Proc Natl Acad Sci USA. 2000;97:315-319.